Cytokines and Transgenic Matrix in Autoimmune Diseases: Similarities and Differences

Association between circulating inflammatory proteins and temporomandibular disorders: insight from a two-sample Mendelian randomization analysis

BACKGROUND

Past studies have indicated links between specific inflammatory proteins in the bloodstream and temporomandibular disorders (TMDs). Nonetheless, there remains the need for further solid research pinpointing the exact causes behind these associations. This Mendelian randomization (MR) study aims to examine the association between 91 circulating inflammatory proteins and TMDs.

METHODOLOGY

The most comprehensive genome-wide association studies available for circulating inflammatory proteins and TMDs was used in this two-sample MR analysis. The association between genetic predispositions to TMDs and levels of circulating inflammatory proteins was explored by various methods, including inverse variance weighted, MR-Egger, weighted median, simple mode, weighted mode, and MR-PRESSO techniques. To evaluate the reliability of these findings, sensitivity analyses such as Cochran's Q test, the MR-Egger intercept test, and a leave-one-out approach were conducted.

RESULTS

Findings indicated significant links between lower levels of circulating CCL4 (odds ratio, OR: 0.9241, 95% confidence interval, CI: 0.8679-0.984, p=0.0138), IL-20 (OR: 0.8615, 95%CI: 0.7566-0.9808, p=0.0243), and TWEAK (OR: 0.8702, 95%CI: 0.7634-0.992, p=0.0375) and an increased risk of TMDs, according to the inverse variance weighted method. Conversely, a higher level of S100A12 in the blood stream was associated with an increased risk of TMDs (OR: 1.1368, 95%CI: 1.0134-1.2752, p=0.0286). Sensitivity analyses confirmed the stability of these outcomes.

CONCLUSION

This study suggests that reduced levels of CCL4, IL-20, and TWEAK are associated with a higher risk of TMDs, alongside an increased risk of TMDs connected to elevated levels of S100A12.

Coexistence of multiple sclerosis and systemic lupus erythematosus - a case report

Purpose

Multiple sclerosis (MS) and systemic lupus erythematosus (SLE) are two autoimmune diseases that are relatively common, especially in women. However, it is extremely rare for them to coexist in a single patient (only 18 cases have been recorded worldwide). Both affect the nervous system and may manifest in identical ways. This creates significant difficulties, both in terms of diagnosis and choice of appropriate therapy.

Case description

A 54-year-old female patient with quadriparesis, superficial sensory disturbance and gait and balance disorders was diagnosed with primary progressive MS according to McDonald's criteria. The magnetic resonance images were typical for MS. Previously, in 2013, she was diagnosed with SLE, treated successfully, and is currently in remission. After excluding neuropsychiatric lupus, ocrelizumab treatment was administered, with good clinical results.

Comment

Adequate differentiation (magnetic resonance imaging, analysis of cerebrospinal fluid, clinical observation) as to whether the patient's symptoms are related to MS or to SLE nervous system involvement is the basis for proper diagnosis and treatment.

Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS

Altered regulatory T cell (Treg) function could contribute to MS. The expression of activating and inhibitory receptors influences the activity of Tregs. Our aim was to investigate T cell phenotypes in relapsing-remitting MS (RRMS) patients at an early phase of the disease. We examined the influence of demographic parameters on the distribution of CD4+ and CD8+ T cell subclasses by generalized linear modeling. We also studied the expression of the following markers-CTLA-4, GITR, PD-1, FoxP3, Helios, CD28, CD62L, CD103-on T cell subsets from peripheral blood with a 14-color flow cytometry panel. We used an antibody array to define the profiles of 34 Th1/Th2/Th17 cytokines in the serum. Expression of PD-1 and GITR on CD4+ and CD8+ Tregs was decreased in RRMS patients. The proinflammatory factors IFN-γ, IL-17, IL-17F, TGFβ-1, TGFβ-3, IL-1SRII, IL-12 p40, sgp130, IL-6sR were significantly increased in RRMS patients. Therefore, a deficiency of PD-1 and GITR immune checkpoints on CD4+ and CD8+ Tregs is a feature of RRMS and might underlie impaired T cell control.